24 April 2007Organon Selects Vivisimo Enterprise Search for 11,000 Pharmaceutical ProfessionalsVivisimo Velocity 5.5 to Increase Productivity and Efficiency with Precision Search ResultsPittsburgh, PA—Vivisimo (vivisimo.com), a leading provider of search software and expertise, today announced the selection of its Vivisimo Velocity 5.5 enterprise search platform by Organon. A global manufacturer of prescription medicines that improve the health and quality of human life, Organon will implement Vivisimo Velocity for more than 11,000 users to increase productivity and efficiency without tradeoffs in security, scalability and fault tolerance that are frequently associated with enterprise search. The Velocity search platform will yield precise and intuitive results that are essential for the pharmaceutical company Organon to impact its core therapeutic fields.
Organon will provide an interactive demonstration of the Velocity deployment at the upcoming European Text Analytics Conference in Amsterdam (textanalyticsnews.com/europe07/) on Friday, April 27th. The summit delivers an innovative and informative meeting point for the unstructured data space and provides attendees the opportunity to gain insight on the latest deployments for text analytics technologies with real success, from the end users themselves. Organon chose Velocity as its enterprise search engine after outperforming against competitive market offerings based on specific criterion; testing for accuracy of results, speed, user interface, scalability, fault tolerance, security, and overall usability. Built for scalability, Velocity 5.5 is a milestone in the evolution of enterprise search technology, empowering customers such as Organon to expand beyond the traditional limitations of departmental inquiries to enterprise-wide search without compromising reliability. As a result, Velocity 5.5 provides a dependable, usable and stable end-user search experience across all corporate departments. "After an exhaustive evaluation of many enterprise search platforms and vendors, Velocity's attention to detail across several critical areas including usability, security, scalability and fault tolerance, made the company stand out as the obvious winner," said Arnold Verstraten, Manager Web Applications eCollaboration of Organon. "Our decision to select Vivisimo's Velocity enterprise search engine platform is a clear indication of our commitment to providing users the best tools necessary to increase efficiency and productivity for the common good of the company." "Besides the tool, the proactive and committed attitude of Vivisimo, which outperformed the competition during the pilot phase, was a strong reason for the selection." "Organon's selection of Velocity is testament to our ability serve the vital pharmaceutical industry. Velocity addresses the need for absolute accuracy and timely delivery of information which is paramount to increasing productivity and efficiency," said Raul Valdes-Perez, CEO of Vivisimo. "With the recent release of Velocity 5.5, we expect our customer roster will expand to include more data intensive organizations such as Organon because it eliminates concerns about enterprise performance."
About the Vivisimo Velocity PlatformThe Vivisimo Velocity platform provides enterprises with innovative search solutions that allow users to access, extract and manipulate all available content, regardless of location. By combining the simplicity of consumer search with the flexibility and control of enterprise software, organizations can reap the benefits of increased user adoption and satisfaction without compromising on performance, scalability, security or the ability to configure a solution specific to its business environment. Based on a service-oriented architecture that enables rapid deployment, Vivisimo Velocity can be up and running in just weeks.
About VivisimoVivisimo does search right by combining the simplicity and innovation of consumer search with the flexibility and control of enterprise software. The company works with customers to understand their goals and quickly deploy solutions that maximize the business value of information—with an interface users love. Vivisimo serves its global client base through headquarters in Pittsburgh, PA, and Paris, France, and partners throughout the world. Please visit vivisimo.com to learn more about us and visit our Search Done Right blog to learn more about enterprise search. About OrganonOrganon creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of innovation and business partnerships, Organon seeks to leverage its position as a leading biopharmaceutical company in each of its core therapeutic fields: fertility, gynecology and selected areas of anesthesia. It has extensive expertise in neuroscience and a rich and focused R&D program. Research areas also include immunology and specific areas of oncology. Organon products are distributed in over 100 countries worldwide, of which more than 50 have an Organon subsidiary. Organon is the human healthcare business unit of Akzo Nobel. Safe Harbor Statement OrganonThis press release may contain forward-looking statements. These forward-looking statements, addressing without limitation such key issues as growth strategy, future financial results, market positions, and product development, are based on current expectations of future events and circumstances and can be identified by the fact that they use words such as "will", "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", "target", "forecast", and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business prospects. Such forward-looking statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these forward-looking statements. Organon BioSciences undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or circumstances, or otherwise. The forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Organon BioSciences' business, particularly but without limitation including general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. ### |
